Ludwig Cancer Research

What Ludwig Cancer Research does

Ludwig Cancer Research is an international collaborative network of cancer researchers founded in 1971 by shipping magnate Daniel K. Ludwig, who bequeathed his conglomerate to fund cancer research. The legal entity, Ludwig Institute for Cancer Research Ltd, is incorporated in Switzerland with operational headquarters in New York. The organization funds and operates eleven wholly-owned research branches and centers embedded within leading academic medical institutions across the United States (Baltimore, Boston Harvard, Boston MIT, Chicago, New York MSK, New York Weill Cornell, Princeton, Stanford) and Europe (Brussels, Lausanne, Oxford), supported by six U.S.-based Ludwig Centers. CEO and Scientific Director Chi Van Dang leads a scientific staff of 501-1,000 organized around five integrated programs: tumor biology, tumor microenvironment, cancer genomics, tumor immunology, and cancer prevention.

The technical platform spans proprietary wet-lab and computational methods. Notable components include TAPS (TET-assisted pyridine borane sequencing) for whole-genome long-read DNA methylation and hydroxymethylation sequencing developed at Ludwig Oxford; CAR-T cell engineering platforms including remote-controlled CAR-T systems resistant to exhaustion; AI-powered personalized cancer vaccine pipelines based on neoantigen identification; liquid biopsy methods using cell-free and circulating tumor DNA; and large-scale quantitative metabolomics for cancer metabolism and dietary intervention studies. Research outputs include peer-reviewed publications, licensed technologies, and sponsored clinical trials spanning lung, ovarian, colorectal, melanoma, and other cancer indications.

Revenue is generated not through commercial product sales but through three streams: charitable donations and foundation grants (the primary funding source supporting nearly $3 billion of cumulative cancer research investment since 1971); technology licensing to pharmaceutical and biotechnology companies (TAPS, CAR-T platforms, liquid biopsy methods); and clinical trial operations conducted in partnership with academic medical centers. The organization is a tax-exempt non-profit governed by a Board of Directors, with no parent company. Its go-to-market model is event-driven, anchored in scientific publications, conference presence (AACR, ASCO, Society for Immunotherapy of Cancer), the triannual Ludwig Link magazine, fortnightly newsletter, and direct licensing engagement with industry partners rather than traditional sales channels.

Name

Ludwig Cancer Research

Legal name

Ludwig Institute for Cancer Research Ltd

Website

https://ludwigcancerresearch.org

Company type

Private

Founded year

1971

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Ludwig Cancer Research is a 54-year-old non-profit international collaborative network conducting basic, translational, and clinical cancer research across eleven global branches at tier-1 academic medical centers, serving cancer patients, academic collaborators, and pharmaceutical licensees.

Ownership category

akta.pro rank

Product category

Cancer Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Medical Oncology (HLAKAFAB), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Cancer research
• Translational oncology
• Clinical trials
• Tumor immunology
• Biomedical licensing

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices12 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Charitable donations and foundation grants: As a non-profit organization established in 1971, Ludwig Cancer Research relies primarily on charitable donations and grants to fund its global research operations. The organization has invested nearly $3 billion in life-changing science since its founding.
2. Technology licensing: Ludwig licenses its proprietary technologies and discoveries to pharmaceutical and biotechnology companies for commercial development. Technologies including TAPS for cancer detection and cellular immunotherapies have been commercialized through licensing agreements.
3. Clinical trial operations: Ludwig sponsors and conducts its own clinical trials, translating discoveries into applications for patient benefit.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Ludwig Cancer Research operates an international collaborative network of scientists conducting basic and translational cancer research across five core programs (tumor biology, tumor microenvironment, cancer genomics, tumor immunology, and cancer prevention). It sponsors its own clinical trials and licenses proprietary technologies—including TAPS epigenetic sequencing, CAR-T cell platforms, personalized cancer vaccine pipelines, and liquid biopsy methods—to pharmaceutical and biotechnology companies for commercial development.

Product overview

Ludwig Cancer Research is an international collaborative network of acclaimed scientists organized as a not-for-profit research organization (Ludwig Institute for Cancer Research) with six U.S.-based Ludwig Centers. The organization operates through a portfolio of research branches at major academic institutions (Stanford, Princeton, Oxford, Harvard, MIT, Lausanne, Brussels, Chicago, MSK, and Weill Cornell) conducting basic science and translational research across five core programs: Tumor biology, Tumor microenvironment, Cancer genomics, Tumor immunology, and Cancer prevention. Notable products include the Ludwig Laboratory for Cell Therapy (launched 2026) focused on personalized T-cell therapies, the Ludwig Princeton Branch (launched 2021) dedicated to cancer metabolism research, and Ludwig Link Magazine for disseminating research findings. The organization combines basic science discovery with clinical trial capabilities and translational research to accelerate development of cancer diagnostics and therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• Ludwig Laboratory for Cell Therapy
• Ludwig Princeton Branch
• Sponsored Cancer Clinical Trials
• Cancer Research Technology Licensing

Quantifiable outcome

• Established 50+ years ago with nearly $3 billion invested in cancer research
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability8 records

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and major.

• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development Partner · 4 February 2026Collaboration on the Ludwig Center at MSK and the Ludwig Laboratory for Cell Therapy. Dr. George Coukos will serve as associate director for cell therapy at the Meyer Cancer Center, which partners with MSK.
• Johns Hopkins UniversitycoreStrategic or Co-development Partner · 4 February 2026Ludwig Institute Scientific Director Chi Van Dang conducts research at Johns Hopkins University. Maimon Hubbi is a postdoctoral researcher in his laboratory studying tumor microenvironment and ferroptosis resistance in pancreatic cancer.
• Weill Cornell MedicinecoreStrategic or Co-development Partner · 2 February 2026Established the Ludwig Laboratory for Cell Therapy at Weill Cornell Medicine's Sandra and Edward Meyer Cancer Center. George Coukos, former Ludwig Lausanne Director, leads the laboratory focusing on developing next-generation personalized T-cell therapies using gene engineering, synthetic biology, and artificial intelligence.
• Princeton UniversitycoreStrategic or Co-development Partner · 13 April 2021Launch of the Ludwig Princeton Branch, wholly dedicated to the study of cancer metabolism and translation of findings into new paradigms for cancer prevention and treatment. Princeton provides expertise in metabolomics, genomics, biology, and computational sciences.
• Vaccitech Oncology LimitedmajorStrategic or Co-development Partner · 18 December 2019Collaboration with Cancer Research UK for Phase I/IIa clinical trial of lung cancer immunotherapy vaccine as first-line NSCLC therapy, combining Vaccitech's technology with Ludwig Institute research.
• Cancer Research UKmajorStrategic or Co-development Partner · 18 December 2019Partnership with Vaccitech Oncology Limited and Ludwig Institute for Cancer Research for Phase I/IIa clinical trial of lung cancer immunotherapy vaccine.
• Rutgers Cancer InstitutecoreStrategic or Co-development PartnerClinical translation partner for Ludwig Princeton Branch discoveries, conducting clinical trials through RWJBarnabas Health and Rutgers Cancer Institute, New Jersey's only NCI-designated Comprehensive Cancer Center.
• University of OxfordcoreStrategic or Co-development PartnerLudwig Oxford Branch is affiliated with the Nuffield Department of Medicine at the University of Oxford. The branch studies signaling pathways influencing cancer initiation and progression, with focus on infection, inflammation, and cancer epigenetics.
• Stanford University School of MedicinecoreStrategic or Co-development PartnerThe Ludwig Center at Stanford University is housed within the Stanford University School of Medicine, dedicated to investigating cancer from the perspective of stem-cell biology and medicine.
• University of Lausanne (UNIL) and Centre Hospitalier Universitaire Vaudois (CHUV)coreStrategic or Co-development PartnerLudwig Lausanne Branch operates in partnership with UNIL and CHUV, with ongoing collaboration and partnership renewal. George Coukos previously directed the Lausanne Branch and established the Department of Oncology.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Emerging players

• BioNTech: Commercial leader in mRNA-based personalized cancer vaccines and immunotherapies, working in overlapping therapeutic modalities to Ludwig's neoantigen vaccine pipeline. Comparable as a translational competitor rather than a direct nonprofit peer.

Direct peers

• Cancer Research UK: The world's largest charitable cancer research funder and an active Ludwig partner (Vaccitech trial, Cancer Grand Challenges). Comparable as a global nonprofit cancer research organization funding multi-institutional translational science.
• Memorial Sloan Kettering Cancer Center: One of the world's leading cancer research and treatment centers, and an active Ludwig partner through the Ludwig MSK center. Comparable as a translational cancer research organization with deep clinical trial infrastructure and overlapping scientific leadership.
• The Francis Crick Institute: Major UK biomedical discovery institute conducting cancer research alongside other disciplines. Comparable as a large-scale nonprofit research organization with international collaborations and translational programs.
• Fred Hutchinson Cancer Center: Seattle-based NCI-designated cancer research center with strong immunotherapy and bone marrow transplantation programs. Comparable as a nonprofit research institute performing basic and translational oncology research with clinical trial operations.
• Cold Spring Harbor Laboratory: Long-standing nonprofit cancer and genomics research institution on Long Island. Comparable as an NCI-designated basic science cancer research organization with academic affiliations and a similar translational research posture.
• Dana-Farber Cancer Institute: Harvard-affiliated cancer research and treatment center with comparable bench-to-bedside translational programs. Direct peer in oncology research intensity, clinical trial operations, and academic medical center affiliation.
• MD Anderson Cancer Center: NCI-designated Comprehensive Cancer Center and one of the largest cancer research institutions globally. Comparable in scale, clinical trial volume, and translational oncology focus.
• Broad Institute of MIT and Harvard: Biomedical and genomic research institute co-located with Ludwig Centers at Harvard and MIT. Comparable as a nonprofit research institute operating across the same academic medical centers with similar genomics and cancer biology programs.

Broad incumbents

• National Cancer Institute (NCI): The US federal government's principal agency for cancer research and training, and a major funder overlapping with Ludwig's partner institutions. Comparable as a large-scale public-sector cancer research organization that sets the funding and translational landscape in which Ludwig operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/results?search_query=ludwig+cancer+research
• LinkedInlinkedin.com/company/ludwig-institute-for-cancer-research
• Xx.com/Ludwig_Cancer
• Facebookfacebook.com/ludwigcancerresearch

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ludwig Cancer Research